Drugs / [18F]Florbetapir
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03080051 | Aug 2016 → Mar 2017 | Alzheimer disease, progressive supranuclear palsy | Molecular NeuroImaging | Completed | No outcome recorded |
| Phase 0 | NCT03071224 | Jun 2016 → Jun 2021 | Alzheimer disease | Invicro | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07012993 | May 2025 → Jun 2030 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Akiva Mintz | Recruiting | No outcome recorded |
| Phase 2 | NCT04305210 | Dec 2019 → Jan 2021 | Alzheimer disease | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01767493 | Nov 2012 → Nov 2013 | multiple sclerosis | Institute for Neurodegenerative Disorders | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-Florbetapir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07012993 ↗ |
| Known as | AV-45 | “18F-florbetapir (AV-45) PET Examination” NCT04305210 ↗ |
| Modality | Diagnostic / imaging agent | “Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-946.” NCT03071224 ↗ |